In addition, such highly activated (CD80+CD86+) B cells significantly expressed RANKL at higher levels than non-activated (CD80–CD86–) B cells (Fig. 1b) in patients with RA, suggesting that robust B-cell activation is required for RANKL expression. This evidence concerns the gene CD80 and rheumatoid arthritis.